ASCO GI 2023 Conference Coverage
Playback speed
10 seconds
ASCO GI 2023 NAPOLI-3 Randomized, Open-Label Phase 3 Study: Liposomal Irinotecan + 5-Fluorouracil/Leucovorin + Oxaliplatin (NALIRIFOX) vs. nab-Paclitaxel + Gemcitabine in Treatment-Naïve Patients With mPDAC
By
ASCO GI 2023 Conference Coverage
FEATURING
Zev A. Wainberg
By
ASCO GI 2023 Conference Coverage
FEATURING
Zev A. Wainberg
398 views
February 1, 2023
Comments 0
Login to view comments.
Click here to Login
Videos